Clearbridge Health Limited is undertaking a renounceable, non-underwritten rights issue of up to 1,279,125,560 new ordinary shares, priced at S$0.002 per share. This represents significant discounts: 53.49% off the theoretical ex-rights price of S$0.0043 and 77.78% off the VWAP of S$0.009 as of September 27, 2024. The rights issue is on a 2-for-1 basis for shareholders recorded on the upcoming Record Date, which will be announced soon.
Key Investor Notes:
- Shareholder Approval & EGM Outcome: Approved on October 23, 2024.
- SGX-ST Quotation Notice: Received on October 25, 2024, allowing trading of rights shares once the rights issue is effective.
- Funds Use: Primarily for working capital with scenarios projecting up to S$2,308,000.
Investors should monitor further announcements and assess if the deep discount aligns with long-term interests in Clearbridge Health Limited’s strategic goals.
